A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting

Phase 3

Sigvotatug Vedotin vs. DocetaxelA Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Sponsor:

Seagen, a wholly owned subsidiary of Pfizer

Code:

NCT06012435

Conditions

Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

sigvotatug vedotin

docetaxel

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-01. This information was provided to ClinicalTrials.gov by Seagen, a wholly owned subsidiary of Pfizer on 2025-04-24.